Onkologie. 2009:3(1):12-18

Chemotherapy and hormonal therapy for breast cancer

Katarína Petráková
Klinika komplexní onkologické péče MOÚ a LF MU Brno

The paper presents an overview of the current options of chemotherapy and hormonal therapy for breast cancer. Neoadjuvant chemotherapy

is mainly indicated in tumours with negative hormone receptors. A combination of anthracyclines and taxanes is recommended.

In particular, patients with a higher risk of relapse benefit from taxanes in adjuvant therapy. Treatment with aromatase inhibitors

should be a part of adjuvant hormonal therapy in postmenopausal patients while, in premenopausal patients, the standard treatment

is tamoxifen. The most effective cytostatic drugs in the treatment for metastatic breast cancer are anthracyclines and taxanes. When

selecting cytostatic drugs, their toxicity and patient preferences need to be taken into consideration.

Keywords: chemotherapy, hormonotherapy, breast cancer.

Published: March 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petráková K. Chemotherapy and hormonal therapy for breast cancer. Onkologie. 2009;3(1):12-18.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendation from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007; 18(12): 1927-1934.
    2. Ring AE, Smith IE, Ashley S, et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004; 91: 2012-2017. Go to original source... Go to PubMed...
    3. Wenzel C, Bartsch R, Hussian D, et al. Invasice ductal carcinoma (IDC) and invasice lobular carcinoma (ILC) of breast differ in response following neoadjuvant therapy with epidoxorubicin anddocetaxel + G-CSF. Breast Cancer Res Treat 2007; 104: 109-114. Go to original source... Go to PubMed...
    4. Kuehn T, Bembenek A, Decker T, et al. A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assuarance. Consensus of the German Society of Senology. Cancer 2005; 103: 451-461. Go to original source... Go to PubMed...
    5. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144. Go to original source... Go to PubMed...
    6. Fischer B, Neony JH, Bryant J, et al. Treatment of lymph-nodenegative, oestrogen receptor positive breast cancer: long-term findings from National Surgical Adjutant and Breast and Bowel Project randomised clinical trials. Lancet 2004; 364: 858-868. Go to original source... Go to PubMed...
    7. Albain K, Barlow W, O´Malley F, et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamid, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen(ER) and/or progesteron (PgR) receptor-positive breast cancer: mature outcomes and new biological correlates on phase III intergroup trial 0100 (SWOG.-8814). Breast Cancer Res Treat 2004a; 88(Suppl 1): (abstrakt 37).
    8. Poole CJ, Earl HM, Hiller I, et al. NEAT Investigators and the SCTBG. Epirubicin and cyclophosphamid, methotrexate and fluorouracil as adjuvant therapy for early breast cencer. N Engl J Med 2006; 355(18): 1851-1862. Go to original source... Go to PubMed...
    9. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel, but not from escalating doxorubicin dose in an adjuvant chemotherapy regiment for patiens with node positive primary breast cancer. J Clin Oncol 2003; 21: 976-983. Go to original source... Go to PubMed...
    10. Roche H, Fumoleau P, Spielman M, et al. Sequential adjutant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patiens: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24(36): 5664-5671. Go to original source... Go to PubMed...
    11. Francis P, Crown J, Di Leo A, et al. BIG 02-98 Collaborative Group. Adjutant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008; 100(2): 121-33. Go to original source... Go to PubMed...
    12. Martin M, Pienkowski T, Mackey J, et al. Breast Cancer International Researche Group 001 Investigators. Adjutant docetaxel for node-positive breast cancer N Engl J Med 2005; 352(22): 2302-2313. Go to original source... Go to PubMed...
    13. Jones, et al. Breast Cancer Res Treat. 2007; 106(suppl 1): S5. Abstract 12.
    14. Howard J, Dunn P, Cannes A, et al. tAnGo: A randomised phase III trial of gemcitabine in paclitaxel containing, epirubicin/cyclophosphamid based, adjuvant chemotherapy. Proc Am Soc ClinOncol 2008; abstract 506. Go to original source...
    15. Cuzik J, AmbroisineL, Davidson N, et al. Use of luteinisinghormone-realising hormone agonists as adjuvant treatment in premenopausal patiens with hormone-receptor-positive breast cancer: a metaanalysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369: 1711-1723. Go to original source... Go to PubMed...
    16. Gnant M, Mineritsch W, Schippinger G, et al. Adjutant supression combined with tamoxifen or anatrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. Breast Cancer Res Treat 2008; 26(Suppl 1) (abstract LBA4). Go to original source...
    17. Peto R, Davies C, and the ATLAS investigators. ATLAS (Adjutant Tamoxifen Longer Against Shorter): international randomised trial of 10 vs 5 years of adjutant tamoxifen among 11,500 women: preliminary results. Breast Cancer Res Treat. 2007; 106(suppl 1): S00 (abstract 48).
    18. Rea DW, Hanley K, Marshall M, et al. aTTom (adjutant Tamoxifen-To offer more): Randomised trial of 10 versus 5 years of adjutant tamoxifen among 6,934 women with estrogen receptor positive (ER+) or ER untested breast cancer - Preliminary results. Proc Am Soc ClinOncol 2008; abstract 513. Go to original source...
    19. Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53. Go to original source... Go to PubMed...
    20. Coates AS, Kashaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cencer: update of study BIG 1-98. J Clin Oncol 207; 25: 486-492.
    21. Goss PE, Unyle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: update findings from NIC CTG MA17. J Natl Cancer Indy 2005; 97: 1262-1271. Go to original source... Go to PubMed...
    22. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer.Proc Am Soc ClinOncol 2007, Abstr 512. Go to original source...
    23. Slamon D, Eiermann W, Robert N, et al. Phase III randomised trial comparing doxorubicin andcyclofosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplastin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cncer Treat 2005; 94(suppl 1): S 5a.
    24. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Herceptin Adjutant (HERA) Trial Study Team. Tratuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 20: 1659-1672. Go to original source... Go to PubMed...
    25. Carrick S, Parker S, Wilcken N, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Databáze Syst Rev 2005, Issue 2, Art No. CD003372,DOI: 10.1002/14651858. Go to original source... Go to PubMed...
    26. Bruzzi P, Del Mastro L, Formani MP, et al. Objective response to chemotherapy as a potential surrogate and point of survival in metastatic breast cancer patiens. J Clin Oncol 2005; 23: 5117-5125. Go to original source... Go to PubMed...
    27. Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patiens with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-2205. Go to original source... Go to PubMed...
    28. Nabholtz JM, Falkon C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III. trial. J Clin Oncol 2003; 21: 968-975. Go to original source... Go to PubMed...
    29. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with metastatic breast cancer:final results of a randomised phase III multicenter trial. J Clin Oncol 2001; 19: 1707-1715. Go to original source... Go to PubMed...
    30. Albain K, Nag S, Cardelillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report on overall surfoval. J Clin Oncol 2004; 22: 510. Go to original source...
    31. Chan S, Romieau G, Hober J, et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patiens (pts). Resultes of a European phase III study. J Clin Oncol 2005; 23: 581. Go to original source...
    32. Boneneterre J, Thurlimann B, Robertson JF, et al. Anastrozol versus tamoxifen in first-line therapy for advanced breast cancer in 668 postmenopausal women:results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 200; 18: 3748-3757.
    33. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozol is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-3767. Go to original source... Go to PubMed...
    34. Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomised trial. J Clin Oncol 2004; 22: 1605-1613. Go to original source... Go to PubMed...
    35. Beslija S, Bonneterre H, Burstein H, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2008; 18: 215-225. Go to original source... Go to PubMed...
    36. Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomised trials. J Clin Oncol 2001; 19: 343-353. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.